Halozyme Therapeutics to Acquire Antares Pharma for Nearly $1 Billion

San Diego, Calif.-based Halozyme Therapeutics is purchasing Ewing, N.J.-headquartered Antares Pharma in a deal valued at approximately $960 million.

The acquisition will give Halozyme access to Antares’ Enhanze enzyme-based drug delivery technology and the company’s auto injector, which has potential uses for delivering a broad range of medications.

Antares has already developed several self-injection products, including the injectable testosterone drugs Xyosted (testosterone enanthate) and Tlando (testosterone undecanoate).

The transaction is expected to close in the first half of 2022.